EMEA ETC

BY ALAN OSBORN
A MAJOR extension of the powers of the European Medicines Evaluation Agency (EMEA) has been proposed by the European Commission as part of a sweeping reform of EU pharmaceutical legislation. At present the EMEA authorises only the use of high profile medicines derived from biotechnology, such as those used for cancer, AIDS, multiple schlerosis and Alzheimers disease among others.

Under the suggested new regime the EMEA would take over the evaluation of all new drugs so ending the right of pharmaceutical manufacturers to gain approvals ...


Full access to this article can be arranged with permission from the client that first ordered it. Please contact us to request access. Entries are uploaded to our archive at least one year after being published by a client – free access is restricted to International News Services journalists for background research only. The article date indicates when copy was filed to a client, not when posted to this archive. Upon client requests, International News Services will remove such articles from the archive or not upload them in the first place. They are included to demonstrate the breadth of topics undertaken by the agency and also to help promote clients’ coverage.